Defining Key Signaling Nodes and Therapeutic Biomarkers in <i>NF1</i> -Mutant Cancers
Clare F. Malone(Arup Group (United States)), Karen Cichowski(Brigham and Women's Hospital), Thomas De Raedt(Children's Hospital of Philadelphia), Rachel Ingraham(Brigham and Women's Hospital), Jody Fromm Longo(Brigham and Women's Hospital), Ophélia Maertens(American Institutes for Research)
Cited by 64
Related Papers
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
|Cell|2015|377
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
|Cancer Discovery|2012|297
Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
|Cancer Cell|2011|259
Elucidating Distinct Roles for <i>NF1</i> in Melanomagenesis
|Cancer Discovery|2012|250
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients
|Human Molecular Genetics|2006|213